$846 | SAVE $149 | Single User
$1692 | SAVE $298 | Site License
$2121 | SAVE $374 | Global License

Ulcerative Colitis: Update Bulletin
[Feb 2016]
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Feb 2016 | 301 | In Stock
Related Topics: FDA , Humira , Ulcerative Colitis

Introduction

Introduction


Gain new KOL insights on the latest events happening in Ulcerative Colitis. Topics covered include opinions regarding Phase III data on Johnson & Johnson’s Stelara (ustekinumab) in Crohn’s disease and the launch of a new study looking at use of the therapy in patients with UC; the recent filing in the US and EU for Amgen’s ABP 501 (a proposed adalimumab biosimilar); the FDA advisory committee’s decision to recommend approval of Celltrion’s CT-P13 (a proposed infliximab biosimilar); as well as opinions on the early development of both Qu Biologics’ QBECO and Protagonist Therapeutics’ PTG 100.


Key Questions Answered in this Update Bulletin:


  • How do KOLs perceive Stelara’s potential in the UC market?

  • How do KOLs perceive the potential of ABP 501 (a Humira biosimilar) in the UC marketplace?

  • What impact do they believe the arrival of biosimilar Humira will have on the market?

  • What do KOLs think of the so-called ‘switching trials,’ which see patients transitioned from an originator therapy to a biosimilar?

  • Do such trials boost confidence in prescribing biosimilars in UC?

  • What are KOLs’ opinions of an FDA committee’s decision to recommend approval of CT-P13, a biosimilar version of Janssen’s Remicade?

  • What do KOLs think of the mechanism of action behind QBECO?

  • Where in the treatment paradigm might QBECO be placed if approved?

  • How clinically attractive is Protagonist Therapeutics’ PTG 100?

  • Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

    Table of Contents
    for Ulcerative Colitis: Update Bulletin [Feb 2016] [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    301 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 15% today! Ulcerative Colitis - Pipeline Review, H1 2017
    Ulcerative Colitis - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical an...
    09 May 2017 by Global Markets Direct USD $1,700 (normally
    USD $2,000)
    More Info
    SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
    The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
    01 Apr 2017 by Current Partnering USD $1,271 (normally
    USD $1,495)
    More Info
    SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
    The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
    01 Feb 2017 by Current Partnering USD $1,271 (normally
    USD $1,495)
    More Info
    SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
    The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
    01 Nov 2016 by Current Partnering USD $1,271 (normally
    USD $1,495)
    More Info
    SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
    The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
    01 Oct 2016 by Current Partnering USD $1,271 (normally
    USD $1,495)
    More Info
    SAVE 15% today! Ulcerative Colitis Global Clinical Trials Review, H2, 2016
    Ulcerative Colitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report,...
    28 Sep 2016 by Global Data USD $2,125 (normally
    USD $2,500)
    More Info
    SAVE 15% today! Ulcerative Colitis: KOL Insight
    Are UC biosimilars a real or perceived threat to branded drugs?Ulcerative colitis (UC) treatment is ...
    01 Sep 2016 by FirstWord Pharma USD $6,715 (normally
    USD $7,900)
    More Info
    SAVE 15% today! Adalimumab Market Analysis: by Applications (Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Ulcerative Colitis, and Others) and Geography – Forecast 2016-2021
    Adalimumab, which is a patent product of the Abott Biotechnology Ltd., is a medication used for trea...
    11 Mar 2016 by USD $4,463 (normally
    USD $5,251)
    More Info
    SAVE 15% today! Ulcerative Colitis: KOL Insight
    Introductionipeline drugs are poised to reshape the way doctors treat ulcerative colitis (UC). But w...
    01 Dec 2015 by FirstWord Pharma USD $6,715 (normally
    USD $7,900)
    More Info
    SAVE 15% today! Ulcerative Colitis: KOL Insight
    IntroductionThe Ulcerative Colitis (UC) treatment market is already undergoing radical change as new...
    03 Dec 2014 by FirstWord Pharma USD $6,715 (normally
    USD $7,900)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Ulcerative Colitis: Update Bulletin [Feb 2016] [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...